LIMITED ATTENDANCE

The attendance at the first-of-its-kind Women’s Cardiometabolic Health and Wellness Masterclass is limited to just 200 seats. This fixed capacity is designed to facilitate the intimate and relaxing environment at the heart of this educational Masterclass concept. Because of the limited nature of this event, interested attendees are encouraged to register early to reserve their spot at Terranea.

CME SYMPOSIA

CME Lunch Symposium

The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis and Treatment

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

CHAIRED BY:Pam R. Taub, MD, FACC
Friday, September 9, 202212:20 PM - 1:20 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Discuss the burden of HF in women, as well as differences in HF etiology and risk factors.
  • Recognize the differences in HF symptom presentation in women in order to identify HF in a timely manner.
  • Summarize important differences and considerations for the application of GDMT in women with HF.
  • Review the efficacy and safety of new and emerging therapies for the treatment of women with HFrEF or HFpEF.
  • Individualize therapy for women with HFrEF or HFpEF according to evidence-based strategies and patient specific risk factors.
EDUCATION GROUP Global UMA Copy
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME Session

Closing the Gaps in the Diagnosis and Management of Aortic Stenosis in Women: The Role of TAVR in Improving Outcomes

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.
Supported by an educational grant from Edwards Lifesciences LLC.
PRESENTED BY:Kimberly A Skelding, MD, FACC, FAHA, FSCAI
Friday, September 9, 20222:30 PM - 3:00 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Recognize the impacts, differences in symptom presentation, and clinical significance of aortic stenosis in women.
  • Outline tailored strategies to screen, diagnose, and risk stratify women with aortic stenosis as a means to identify patient candidates who may benefit from appropriate treatment.
  • Summarize the updated guidelines and evidence from recent clinical trials and real-world studies of TAVR vs. SAVR in women with AS across the risk continuum.
  • Develop individualized treatment plans for women with severe aortic stenosis based on updated evidence, guidelines, and patient-specific clinical presentation and needs.
PACE Logo Final PACE Logo Red And Gray
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME Symposium

Optimizing Lipid Lowering Therapy in Women: Gaps Perspectives and Advances

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.

CHAIRED BY:Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Saturday, September 10, 202211:40 AM - 12:30 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Recognize the burden of ASCVD risk in women, and challenges with optimizing statin therapy
  • Explain the need for the early and adequate intensification of LDL-C lowering therapy beyond statins in women to address ASCVD risk.
  • Summarize the efficacy and safety of PCSK9 inhibitors across trial and real-world studies
  • Discuss the rationale, efficacy, and safety of novel LDL-C lowering agents and their potential impact in addressing current gaps in lipid-lowering therapy in women.
  • Select individualized treatment strategies to optimize lipid-lowering therapy in women that prioritize the early initiation and intensification of therapy to reduce ASCVD risk.
PACE Logo Final PACE Logo Red And Gray
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CMHC  Sponsors & Partners

Join this year’s illustrious brand partners and sponsors and take your 2022 goals to the next level.